In vitro antitumor screening of some polysubstituted pyrazole analogs

Saudi Pharmaceutical Journal

Volumn 13, Issue 2-3, 2005, Pages 89-96

  Al Saadi, Mohammed S ^a   Rostom, Sherif A F ^a   Faid Allah, Hassan M ^a  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

1,2,4 Oxadiazole; 1,2,4 Triazole; 4 Hydroxy 1H pyrazoles; Antitumor screening

Indexed keywords

1 (4 CHLOROPHENYL) 4 HYDROXY 1H PYRAZOLE 3 CARBOXYLIC ACID HYDRAZIDE DERIVATIVE; 1,2,4 OXADIAZOLE DERIVATIVE; 1,2,4 TRIAZOLE DERIVATIVE; 5 [1 (4 CHLOROPHENYL) 4 HYDROXY 1H PYRAZOL 3 YL] 1,3,4 OXADIAZOL 2 ONE; 5 [1 (4 CHLOROPHENYL) 4 HYDROXY 1H PYRAZOL 3 YL] 2 PHENYL 1,3,4 OXADIAZOLE; 5 [1 (4 CHLOROPHENYL) 4 HYDROXY 1H PYRAZOL 3 YL] 4 CYCLOHEXYL 1,2,4 TRIAZOLINE 3 THIONE; PIRAZOFURIN; PYRAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; DRUG SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY;

EID: 18744386967     PISSN: 13190164     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Sammes PG. Topics in Antibiotic Chemistry, Ellis Horwood Limited , John Wiley and Sons, New York, p. 189 (1982).
2. Ishida J, Ohtsu H, Tachibana Y, Nakanishi Y, Bastow KF, Nagai M, Wang HK, Itokawa H, Lee KH. Antitumor Agents. Part 214: Synthesis and evaluation of curcumin analogues as cytotoxic agents. Bioorg Med Chem 2002; 10: 3481-3487.
3. Baraldi PG, Pavani MG, Nunez M del C, Brigidi P, Vitali B, Gambari R, Romagnolia R. Antimicrobial and antitumor activity of N-heteroimmine-1,2,3- dithiazoles and their transformation in triazolo-, imidazo-, and pyrazolopirimidines. Bioorg Med Chem 2002; 10: 449-456.
4. Baraldi PG, Beria I, Cozzi P, Geroni C, Espinosa A, Gallo MA, Entrena A, Bingham JP, Hartley JA, Romagnolia R. Cinnamoyl nitrogen mustard derivatives of pyrazole analogues of tallimustine modified at the amidino moiety: design, synthesis, molecular modeling and antitumor activity studies. Bioorg Med Chem 2004; 12: 3911-3921.
5. Storer R, Ashton CJ, Baxter AD, Hann MM, Marr CLP, Mason A.M, Mo CL, Myers P L, Noble SA, Penn HR, Wier NG, Niall G, Woods JM, Coe PL. The synthesis and antiviral activity of 4-fluoro-1-β-D-ribofuranosyl-1H-pyrazole-3- carboxamide. Nucleosides Nucleotides 1999; 18 (2): 203-216.
6. Moukha-chafiq O, Taha ML, Lazrek HB, Vasseur J-J, Pannecouque C, Witvrouw M, De Clercq E. Synthesis and biological activity of some 4-substituted 1-[1-(2,3-dihydroxy-1-propoxy)methyl-1,2,3-triazol-(4&5)-ylmethyl] -1H-pyrazolo[3,4-d]pyrimidines., Il Farmaco 2002; 57: 27-32.
7. Shen DM, Shu M, Mills SG, Chapman KT, Malkowitz L, Springer MS, Gould SL, DeMartino JA, Siciliano SJ, Kwei GY, Carella A, Carver G, Holmes K, Schleif WA, Danzeisen R, Hazuda D, Kessler J, Lineberger J, Millerd MD, Eminid EA. Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 1: Discovery and SAR study of 4-pyrazolylpiperidine side chains Bioorg Med Chem Lett 2004; 14: 935-939.
8. El-Gaby M SA, Atalla AA, Gaber AM, Abd Al-Wahab KA. Studies on aminopyrazoles: antibacterial activity of some novel pyrazolo[1,5-a]pyrimidines containing sulfonamido moieties. Il Farmaco 2000; 55: 596-602.
9. Kaymakcioglu BK, Rollas S. Synthesis, characterization and evaluation of antituberculosis activity of some hydrazones. Il Farmaco 2002; 57: 595-599.
10. Finn J, Mattia K, Morytko M, Ram S, Yang Y, Wu X, Mak E, Gallant P, Keith D. Potent and selective series of pyrazole bacterial methionyl-tRNA synthetase inhibitors. Bioorg Med Chem Lett 2003; 13: 2231-2234.
11. Fahmy HTY, Rostom SHAF, Bekhit AA. Synthesis and antitumor evaluation of new polysubstituted thiazole and derived thiazolo[4,5-d]pyrimidine systems. Arch Pharm Pharm Med Chem 2002; 335: 213-222.
12. Fahmy HTY, Rostom SHAF, Saudi MNS., Zjawiony JK, Robins DJ. Synthesis and in-vitro Anticancer evaluation of some new fluorinated thiazolo[4,5-d] pyrimidines. Arch Pharm Pharm Med Chem 2003; 336: 216-225.
13. Rostom SHAF, Shalaby MA, El-Demellawy MA. Polysubstituted pyrazoles, Part 5. synthesis of new 1-(4-chlorophenyl)-4-hydroxy-1H-pyrazole-3-carboxylic acid
14. Grever MR, Schepartz SA, Chabner BA. The national cancer institute cancer drug discovery and development program. Seminars Oncol 1992; 19: 622-638.
15. Boyd MR, Paull KD. Practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen. Drug Rev Res 1995; 34: 91-109.
16. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Jangley J, Cronisie P, Viagro-Wolff A, Gray-Goodrich M, Campell H, Boyd M. Feasibility of a high flux anticancer drug screen utilizing a derive panel of human tumor cell lines in culture. J Natl Cancer Inst 1991; 83: 757-766.
17. DeVita VT Jr, Hellman S, Rosenberg SA. Cancer Principles and Practice of Oncology, 6th Ed., Lippincott Williams and Wilkins, Philadelphia, USA, p. 349 (2001).